New formulation
for easy on farm use
  • Rapid onset of immunity3
  • No priming dose required
  • Simple to use, single dose intra-nasal spray 
  • Available in convenient 10 & 50 dose packs
DOWNLOAD BROCHURE
WHY CHOOSE RHINOGARD IBR VACCINE?
  • Immune mediators present in the respiratory tract secretions of cattle are important for protection against respiratory disease caused by IBR
  • The concentration of these immune mediators at 3-4 days post vaccination have been found to be associated with a decline in viral replication2
A comparative study was conducted with Rhinogard vs Bovilis MH+IBR3
 
  • Rhinogard is the only vaccine to stimulate BOTH;
- a local specific and non-specific immune response

PLUS

- a systemic immune response (blood antibodies)
  • Rhinogard provides rapid onset of protection as only one dose is required (no need to wait 14 days after a second injection)
No local immune response in the respiratory tract after Bovilis MH+IBR was shown in this study3.

THE BENEFITS OF USING RHINOGARD IBR WITH BOVI-SHIELD MH-ONE

The most comprehensive vaccination program utilising Rhinogard includes co-administration of Bovi-Shield MH-ONE.

The flow chart demonstrates that when both vaccines are used together, there are two different stages in the disease process where the cascade of events leading up to a BRD outbreak are inhibited.

Rhinogard works at the early stage of disease development to reduce the impact of IBR in the chain of events. For cases where other viruses are involved early on, Bovi-Shield works later to prevent pneumonia’s caused by MH. Together, they have a broader impact on pulling up the course of disease than either product used in isolation.

In addition, both vaccines are single dose and are rapidly efficacious.
THE ADVANTAGES OF RHINOGARD VS BOVILIS MH + IBR
Rhinogard IBR IBR in Bovilis MH + IBR
Single dose administration, no backgrounding/priming dose necessary Two doses required, backgrounding/priming dose necessary
Local specific and non-specific immune response in the respiratory tract1,2,3 No local immune response in the respiratory tract3
Prevention of virus shedding post challenge in all but one animal in pen trials3 Reduction of virus shedding in terms of peak virus titres and duration of excretion only4
Field studies for registration show vaccine improved ADG and FCE3 No field studies conducted for registration4
No injection required, no local vaccine site reactions Local vaccine site reactions expected with injectable adjuvanted vaccines
Questions?
Call Zoetis on 1800 814 883 or your local vet for more information


Zoetis Australia Pty Ltd. Level 6, 5 Rider Boulevard Rhodes NSW 2138
For more information visit: www.zoetis.com.au/LS
© 2023 Zoetis Inc. All rights reserved.

References:
1. Todd JD Immune response to Infectious Bovine Rhinotracheitis Virus (IBRV) following natural infection or vaccination by intranasally or parenterally administered vaccine International Symposium on Immunity in Infection of the Respiratory System in Man and Animals London 1974. Develop. Biol. Standard. 28:526-529 (Karger, Basel 1975).
2. Todd JD et al Interferon in Nasal Secretions and Sera of Calves After Intranasal Administration of Avirulent Infectious Bovine Rhinotracheitis Virus:Association of Interferon in Nasal Secretions with Early Resistance to Challenge with Virulent Virus Infect. Immun. 1972, 5(5):699. 3. Zoetis data on file for Rhinogard liquid vaccine. 4. APVMA Advice Summary Application for registration of a chemical product; Coopers Bovilis MH & IBR Respiratory Disease Vaccine for Cattle: KP25S_F39 Version 2 Issued: 14/08/2007

DISCLAIMER: Rhinogard works at the early stage of disease development to reduce the impact of IBR in the chain of events. For cases where other viruses are involved early on, Bovi-Shield works later to prevent pneumonia’s caused by MH. Together, they have a broader impact on pulling up the course of disease than either product used in isolation.